These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 31934889)

  • 1. Successful treatment with brentuximab vedotin for relapsed and refractory adult T cell leukemia.
    Oka S; Ono K; Nohgawa M
    Anticancer Drugs; 2020 Jun; 31(5):536-539. PubMed ID: 31934889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after stem cell transplantation.
    Taçyıldız N; Tanyıldız HG; Ünal E; Dinçaslan H; Asarcıklı F; Aksoy BA; Vatansever G; Yavuz G
    Turk J Pediatr; 2019; 61(5):671-676. PubMed ID: 32104998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression.
    Jacobsen ED; Sharman JP; Oki Y; Advani RH; Winter JN; Bello CM; Spitzer G; Palanca-Wessels MC; Kennedy DA; Levine P; Yang J; Bartlett NL
    Blood; 2015 Feb; 125(9):1394-402. PubMed ID: 25573987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brentuximab vedotin use in pediatric anaplastic large cell lymphoma.
    Agrusa JE; Egress ER; Lowe EJ
    Front Immunol; 2023; 14():1203471. PubMed ID: 37275877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30-Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial.
    Kim SJ; Yoon DH; Kim JS; Kang HJ; Lee HW; Eom HS; Hong JY; Cho J; Ko YH; Huh J; Yang WI; Park WS; Lee SS; Suh C; Kim WS
    Cancer Res Treat; 2020 Apr; 52(2):374-387. PubMed ID: 31476851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis.
    Kim YH; Prince HM; Whittaker S; Horwitz SM; Duvic M; Bechter O; Sanches JA; Stadler R; Scarisbrick J; Quaglino P; Zinzani PL; Wolter P; Eradat H; Pinter-Brown LC; Ortiz-Romero PL; Akilov OE; Trotman J; Taylor K; Weichenthal M; Walewski J; Fisher D; McNeeley M; Gru AA; Brown L; Palanca-Wessels MC; Lisano J; Onsum M; Bunn V; Little M; Trepicchio WL; Dummer R
    Eur J Cancer; 2021 May; 148():411-421. PubMed ID: 33794441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study.
    Dummer R; Prince HM; Whittaker S; Horwitz SM; Kim YH; Scarisbrick J; Quaglino P; Zinzani PL; Wolter P; Eradat H; Pinter-Brown L; Sanches JA; Ortiz-Romero PL; Akilov OE; Geskin L; Huen A; Walewski J; Wang Y; Lisano J; Richhariya A; Feliciano J; Zhu Y; Bunn V; Little M; Zagadailov E; Dalal MR; Duvic M
    Eur J Cancer; 2020 Jul; 133():120-130. PubMed ID: 32502876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical experience of using brentuximab-vedotin as therapy in relapsed/refractory Hodgkin's lymphoma at Hospital Guillermo Grant Benavente, Concepción, Chile].
    Vidal C; Figueroa F; Briones V; Micolich V; Chandia M
    Rev Med Chil; 2023 Oct; 151(10):1361-1366. PubMed ID: 39093139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful Treatment of an Aggressive Adult T-cell Leukemia/Lymphoma with Strong CD30 Expression Using Brentuximab Vedotin as Combination and Maintenance Therapy.
    Baba Y; Sakai H; Kabasawa N; Harada H
    Intern Med; 2023 Feb; 62(4):613-616. PubMed ID: 35871596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia.
    Narayan R; Blonquist TM; Emadi A; Hasserjian RP; Burke M; Lescinskas C; Neuberg DS; Brunner AM; Hobbs G; Hock H; McAfee SL; Chen YB; Attar E; Graubert TA; Bertoli C; Moran JA; Bergeron MK; Foster JE; Ramos AY; Som TT; Vartanian MK; Story JL; McGregor K; Macrae M; Behnan T; Wey MC; Rae J; Preffer FI; Lesho P; Duong VH; Mann ML; Ballen KK; Connolly C; Amrein PC; Fathi AT
    Cancer; 2020 Mar; 126(6):1264-1273. PubMed ID: 31860140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-CD30 antibody-drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives.
    Prince HM; Hutchings M; Domingo-Domenech E; Eichenauer DA; Advani R
    Ann Hematol; 2023 Jan; 102(1):13-29. PubMed ID: 36512081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brentuximab vedotin as a bridge to allogeneic stem-cell transplantation for refractory or relapsing patients with CD30 positive anaplastic or T-cell non-Hodgkin lymphomas: a study on behalf of the SFGM-TC.
    Garciaz S; Loschi M; De Masson A; Biard L; Mercier M; Tomowiak C; Delage J; Labussiere-Wallet H; Sibon D; Cassuto O; Borel C; Cornillon J; Nimubona S; Charbonnier A; Brice P; Socié G; Bouabdallah R; de Latour RP; de Fontbrune FS
    Leuk Lymphoma; 2019 Nov; 60(11):2802-2805. PubMed ID: 31014144
    [No Abstract]   [Full Text] [Related]  

  • 13. Phase II trial of brentuximab vedotin in relapsed/refractory germ cell tumors.
    Ashkar R; Feldman DR; Adra N; Zaid MA; Funt SA; Althouse SK; Perkins SM; Snow CI; Lazzara KM; Sego LM; Quinn DI; Hanna NH; Einhorn LH; Albany C
    Invest New Drugs; 2021 Dec; 39(6):1656-1663. PubMed ID: 34031784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/II clinical trial of brentuximab vedotin for pretreated Japanese patients with CD30-positive cutaneous T-cell lymphoma.
    Hirai Y; Sakurai J; Yoshida S; Kikuchi T; Mitsuhashi T; Miyake T; Fujimura T; Abe R; Fujikawa H; Boki H; Suga H; Shibata S; Miyagaki T; Shimauchi T; Kiyohara E; Kawakami Y; Morizane S
    J Dermatol; 2024 Aug; 51(8):1037-1049. PubMed ID: 38874430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful reversal of severe liver function impairment with Brentuximab vedotin in multiply relapsed/refractory classical Hodgkin lymphoma.
    Spathas N; Belia M; Giannikos T; Arapaki M; Efstathopoulou M; Tsourouflis G; Gainaru G; Asimakopoulos J; Tsaftaridis P; K Angelopoulou M; Plata E; Konstantopoulos K; P Vassilakopoulos T
    J BUON; 2019; 24(6):2483-2489. PubMed ID: 31983123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
    Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
    Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hope After Salvage Therapy Fails: Novel Agents for Relapsed/Refractory Hodgkin Lymphoma.
    Kallam A; Vose JM
    Oncology (Williston Park); 2019 May; 33(5):192-8. PubMed ID: 31095720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging Therapies in Relapsed and Refractory Hodgkin Lymphoma: What Comes Next After Brentuximab Vedotin and PD-1 Inhibition?
    Othman T; Herrera A; Mei M
    Curr Hematol Malig Rep; 2021 Feb; 16(1):1-7. PubMed ID: 33409966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma.
    Shea L; Mehta-Shah N
    Curr Hematol Malig Rep; 2020 Feb; 15(1):9-19. PubMed ID: 32016790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brentuximab vedotin in T-cell lymphoma.
    Van Der Weyden C; Dickinson M; Whisstock J; Prince HM
    Expert Rev Hematol; 2019 Jan; 12(1):5-19. PubMed ID: 30526166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.